News
Health-care companies rose as investors bet on anti-obesity products. Omada Health shares jumped after the maker of digital products that help track diet and other diabetes factors made its ...
Weight-loss injections are taking off in Switzerland. But despite obesity being more prevalent among men, it is women who are ...
The Independent on MSN7h
Weight-loss drugs are already dropping in price; could they go even lower?The price of weight loss drugs is falling ... Despite the price drops, the drugs remain costly. Novo Nordisk cut the price of ...
The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...
Mr. Funk was the managing editor of Pleroma Media, and worked as a breaking news reporter at The Messenger after spending 25 ...
Novo Nordisk's flagship diabetes and weight-loss drugs, Ozempic and Wegovy, have come under heightened scrutiny after the ...
Shares in pharmaceuticals group Novo Nordisk (NVO) remained in good shape today despite reports that its weight loss drugs ...
In the past, studies in type-2 diabetes patients have linked Ozempic to the condition called non-arteritic anterior ischemic ...
14h
The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide ...
The European Medicines Agency has identified a rare eye condition risk linked to Novo Nordisk’s semaglutide drugs.
Human insulin presents Indian companies an opportunity estimated at Rs 450 crore per annum in India and $157 million/annum in ...
The European Medicines Agency’s safety committee found that an eye condition called NAION is a “very rare” side effect of semaglutide, a key ingredient in diabetes and obesity drugs. It could affect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback